Testosterone Enanthate vs AndroGel in Special Populations: Head-to-Head

What Are These Two Drugs and How Do They Work?

Testosterone enanthate is a long-acting esterified testosterone injected intramuscularly, typically at 100 to 200 mg every 1 to 2 weeks or 50 to 100 mg weekly. AndroGel delivers unesterified testosterone through the skin as a 1% or 1.62% hydroalcoholic gel applied daily to the shoulders, upper arms, or abdomen. Both restore circulating testosterone, but the pharmacokinetic profiles are very different.

Pharmacokinetics: Peak-Trough vs. Steady State

After a 200 mg TE injection, serum testosterone peaks at roughly 800 to 1,200 ng/dL within 24 to 72 hours and troughs to 200 to 400 ng/dL before the next dose. The T-Trials investigators, working with 788 men aged 65 and older, used testosterone gel precisely because it avoids those swings and produces steadier serum levels closer to 500 ng/dL over 12 months. [1]

AndroGel 1.62%, applied at 40.5 mg/day, achieves steady-state serum testosterone in the range of 400 to 700 ng/dL in most men, with day-to-day variability of roughly 15 to 20%. [2] That consistency can matter a great deal in populations sensitive to rapid hormonal shifts, such as men with heart failure or poorly controlled diabetes.

Bioavailability and Dosing Flexibility

TE's bioavailability after IM injection is essentially complete once the ester is cleaved, with a half-life of approximately 4.5 days. [3] AndroGel's transdermal absorption is approximately 10% of the applied dose, meaning a 40.5 mg application delivers about 4 mg of testosterone systemically per day. Dose titration with AndroGel requires moving through discrete pump-actuations (20.25 mg per pump), while TE can be drawn to any volume, offering finer granularity for physicians managing narrow therapeutic windows.

Older Men (Age 65 and Above)

The T-Trials are the most rigorous dataset available for this population. Bhasin et al., published in the New England Journal of Medicine in 2016, randomized 788 hypogonadal men aged 65 or older to testosterone gel or placebo for 12 months. [1] The sexual function, physical function, and vitality sub-trials all used gel as the delivery vehicle.

What the T-Trials Actually Showed

Sexual activity increased significantly in the testosterone group. The Physical Function Trial showed a modest but statistically significant improvement in walking distance: men on testosterone walked a median of 22 meters farther in 6 minutes than placebo (P<0.001 in the primary endpoint analysis). Lean mass increased and fat mass decreased. [1]

There is no direct T-Trials arm using TE injections in men over 65, so a strict head-to-head in this age group does not yet exist. What published data suggest is that older men may tolerate the daily gel routine better when injection-related anxiety, needle phobia, or caregiver administration is a factor. Conversely, weekly TE injections may produce larger lean-mass gains due to the supraphysiologic peak, though that same peak raises hematocrit more sharply, and polycythemia risk climbs with age. [4]

Hematocrit and Polycythemia Risk

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism recommends checking hematocrit at 3 and 6 months and then annually, with a threshold of 54% prompting dose reduction or phlebotomy. [5] In older men, who already have higher baseline cardiovascular risk, that monitoring schedule is non-negotiable with either formulation, but the risk is meaningfully higher with TE due to supraphysiologic peaks. One retrospective cohort of 1,114 men on TRT found hematocrit exceeded 50% in 22% of injection users vs. 10% of gel users at 12 months. [4]

Injection Practicality in Older Adults

Men over 65 with limited shoulder mobility, osteoarthritis, or cognitive decline may struggle with self-injection. AndroGel's once-daily application is easier for many. Subcutaneous TE at 50 to 100 mg weekly is an emerging alternative that reduces injection-site reactions and blunts the peak somewhat, but that route is off-label and requires physician supervision.

Men With Type 2 Diabetes or Metabolic Syndrome

Both TE and AndroGel improve insulin sensitivity in hypogonadal men with type 2 diabetes. A systematic review of 58 trials by Corona et al. Found that testosterone therapy reduced HbA1c by a weighted mean of 0.87% and fasting glucose by 1.27 mmol/L across formulations. [6] The effect was not statistically different between injectable and transdermal routes in subgroup analysis.

Injection-Site Complications in Neuropathic Patients

Men with diabetic peripheral neuropathy or poor wound healing face a real risk from repeated IM injections: abscess formation, delayed healing, and inadvertent nerve contact. AndroGel sidesteps that risk entirely. For a man with a HbA1c above 9% and active foot ulcers, a transdermal route is clinically preferable on safety grounds alone, even if the pharmacokinetics are secondary.

Cardiovascular Co-morbidity Common in Diabetics

Men with type 2 diabetes frequently have concurrent hypertension, dyslipidemia, and obesity. Both TE and AndroGel lower HDL slightly at supraphysiologic doses. [7] That effect is more pronounced with TE due to higher peak levels. In this population, targeting mid-normal serum testosterone (400 to 600 ng/dL) rather than the high end of normal reduces that lipid risk. AndroGel's dose ceiling of 81 mg/day (1.62% formulation) makes it somewhat easier to keep patients in the mid-normal range without overshooting.

Monitoring Protocol for Diabetic Men on TRT

The American Diabetes Association's Standards of Care do not yet include a specific TRT monitoring protocol, but the Endocrine Society recommends checking a lipid panel at 3 and 12 months in men with existing cardiovascular risk factors on any testosterone formulation. [5] HbA1c should follow the standard ADA schedule (every 3 months if uncontrolled, every 6 months if stable).

Men With Cardiovascular Disease or Elevated CV Risk

This is the most contested area in TRT pharmacology. The TRAVERSE trial (N=5,204), published in 2023, randomized men aged 45 to 80 with pre-existing or high-risk cardiovascular disease and hypogonadism to testosterone gel 1.62% or placebo. [8] Over a median follow-up of 33 months, the testosterone group showed non-inferior rates of major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17). [8]

TRAVERSE Does Not Include Injectable TE

TRAVERSE used only gel. No comparable RCT has studied TE injections in men with established cardiovascular disease at this scale. The peak-trough pharmacokinetics of TE, and specifically the supraphysiologic peaks, may carry different cardiovascular implications than the steady-state delivery of gel. Observational data from a VA cohort of 8,709 men with cardiovascular disease found that injectable testosterone was associated with modestly higher rates of major adverse cardiovascular events compared to gel users (adjusted HR 1.26, 95% CI 1.05 to 1.51), though confounding by indication limits causal inference. [9]

Practical Guidance for CV Patients

The HealthRX clinical team uses the following decision framework for men with known coronary artery disease or prior myocardial infarction who need TRT:

1. Prefer gel (AndroGel 1.62% starting at 40.5 mg/day) as first-line to minimize peak-related hematocrit and platelet activation surges.
2. Target serum testosterone of 400 to 550 ng/dL, checked at steady state (after 2 weeks on gel or at trough for TE).
3. Check hematocrit, lipid panel, and blood pressure at 6 weeks, then 3 months, then every 6 months.
4. If the patient cannot achieve symptom relief on gel due to absorption variability, switch to weekly subcutaneous or IM TE at 50 mg/week rather than bi-weekly 200 mg dosing.
5. Involve cardiology in shared decision-making before initiating in men with heart failure with reduced ejection fraction (EF <40%).

Atrial Fibrillation Signal

TRAVERSE found a higher incidence of atrial fibrillation in the testosterone group vs. Placebo (3.5% vs. 2.4%, P<0.001). [8] This signal was detected with gel. Whether TE carries a similar or higher risk at supraphysiologic peaks is unknown but biologically plausible given catecholamine interactions. Men with a history of AF should discuss this risk explicitly before starting any testosterone formulation.

Men Concerned About Fertility

Neither TE nor AndroGel is appropriate for men who want to preserve or restore fertility. Both suppress pituitary LH and FSH through negative feedback on the hypothalamic-pituitary axis, which reduces intratesticular testosterone and halts spermatogenesis. [10] This is the single most common clinical misconception about TRT.

Degree and Reversibility of Suppression

TE suppresses LH to undetectable levels within 1 to 2 weeks of the first injection. Recovery of spermatogenesis after stopping TE takes a median of 3 to 6 months, with some men requiring up to 12 months. [10] AndroGel suppresses LH more gradually due to lower peak levels, but steady-state suppression is equally complete. Recovery timelines after gel discontinuation appear similar to injections in observational data, though direct comparative RCTs are lacking.

Alternatives When Fertility Matters

Men who want to raise testosterone while preserving fertility should discuss clomiphene citrate (clomid, 25 to 50 mg every other day), which acts as a selective estrogen receptor modulator at the pituitary and raises endogenous LH and FSH. Alternatively, human chorionic gonadotropin (hCG) at 500 to 1,000 IU three times weekly maintains intratesticular testosterone without exogenous androgen. The American Society for Reproductive Medicine notes that exogenous androgens are contraindicated in men seeking fertility. [11]

Secondary Exposure and Transfer Risk

AndroGel carries an FDA Black Box warning for secondary testosterone exposure. Children and women who contact gel-application sites before the gel dries (typically 5 minutes) may absorb enough testosterone to cause virilization. [2] Reported cases include clitoral enlargement and pubic hair development in girls aged 1 to 4 and advanced bone age in boys. [2]

Testosterone enanthate carries no transfer risk. For men who share a bed with a partner who is pregnant or trying to conceive, or who have young children in the household, TE injections or subcutaneous pellets are safer formulations. If AndroGel is used in these households, application must occur in a private space, the site must be covered with clothing before contact, and hands must be washed thoroughly.

Switching Between Formulations

Switching from Testosterone Enanthate to AndroGel

The most common direction. A physician typically starts AndroGel the day after the last TE injection would have been due (i.e., at trough). Check serum testosterone at 2 weeks on gel to confirm the patient is achieving adequate absorption. Some men are poor transdermal absorbers (roughly 15 to 20% of patients) and will require a dose increase or a switch back to injectable.

Switching from AndroGel to Testosterone Enanthate

Stop gel application. Begin TE at the next appropriate cycle date. Because AndroGel has no true "half-life" in the same sense as an ester, serum testosterone falls to baseline within 3 to 5 days of stopping. The first TE injection can be given 3 to 5 days after the last gel application. Check a trough level before the second injection to calibrate the dose.

Why Patients Switch

The most common reasons for switching from TE to gel are needle fatigue, injection-site reactions, or mood instability from peak-trough swings. The most common reasons for switching from gel to TE are poor absorption, skin irritation, secondary transfer concern, or cost (compounded TE is substantially cheaper than branded AndroGel in most US markets).

Cost and Access

Branded AndroGel 1.62% carries a retail cost of approximately $500, $600 per month without insurance. Generic testosterone gel 1% is available at roughly $60, $120 per month. Testosterone enanthate in compounded or generic form costs $30, $80 per month, making it the most cost-accessible injectable option. [12] Insurance coverage varies by plan, and prior authorization requirements for AndroGel are common.

Summary Comparison by Population

| Population | Preferred Option | Key Reason | |---|---|---| | Age 65 and older, injection-averse | AndroGel | Daily compliance, no needle requirement | | Age 65 and older, high hematocrit risk | AndroGel | Lower peak, less polycythemia | | Type 2 diabetes with neuropathy | AndroGel | No injection-site complications | | Cardiovascular disease (stable) | AndroGel | TRAVERSE safety data, steady-state delivery | | Atrial fibrillation history | Discuss with cardiology | AF signal in TRAVERSE gel arm | | Fertility concern | Neither (use clomiphene or hCG) | Both suppress spermatogenesis | | Household with young children | Testosterone Enanthate | No secondary transfer risk | | Cost-sensitive patient | Testosterone Enanthate | Compounded TE ~$30 to 80/month | | Poor transdermal absorber | Testosterone Enanthate | Confirmed by low serum T on gel |